Nucleoside-Lipid-Based Nanocarriers for Sorafenib Delivery

Abstract

Abstract Although the application of sorafenib, a small inhibitor of tyrosine protein kinases, to cancer treatments remains a worldwide option in chemotherapy, novel strategies are needed to address the low water solubility ( 80 μM) revealed a total cancer cell death in all cases. These results highlight the potential of nucleoside-lipid-based SLNs as drug delivery systems.

Keywords

• Sorafenib
• Solid lipid nanoparticles
• Nucleolipids
• Hepatocarcinoma
• Breast carcinoma
• Luminal B